← Oncology Approval Tracker

FDA DECISION ·

Brukinsa tablets

zanubrutinib · BeOne Medicines USA

FDA approvalNew formulationB-cell malignancies
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A 160 mg scored tablet presentation for adults with Waldenström macroglobulinemia or chronic lymphocytic leukemia/small lymphocytic lymphoma.

LAMPGEN ANALYSIS

Why it matters

The tablet gives patients an alternate presentation for these established BTK inhibitor indications.

What research teams should watch

Confirm the prescribed strength and total daily dose when transitioning from capsules, and track the relevant use’s regulatory pathway separately.

PRIMARY RECORDS

Sources